Qihan Bio

Co-founded in 2017 by two pioneers in genome editing technology, Qihan Biotech has world-leading capabilities in multiplexable genome editing as well as vast experience in Immune shielding. We apply these tools in both human stem cells and animal germline cells to deliver novel immune-privileged cell and organ therapies.

Use multiplexable genome editing in combination with extensive knowledge in transplantation immunology to create immunologically privileged allogenic cells and xenogeneic organs for use as therapies to treat cancer, organ failure and other important medical conditions